EUCTR2010-020077-16-DK进行中（未招募）不适用
A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 WEEK OPEN LABEL EXTENSIO
Pfizer Ltd., Ramsgate Road, Sandwich, kent, CT13 9NJ, United Kingdom0 个研究点目标入组 200 人开始时间: 2011年5月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject eligibility should be reviewed and documented by an appropriately qualified member
- •of the investigator’s study team before subjects are included in the study.
- •- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study;
- •- Subjects who are willing and able to comply with scheduled visits, treatment plan,
- •laboratory tests, and other study procedures.
- •- Subjects must meet all of the following inclusion criteria to be eligible for enrollment
- •into the study:
- •1. Diagnosis of axial spondyloarthritis, as defined by the ASAS criteria (excluding
- •active uncontrolled inflammatory bowel disease or uveitis) of >3 months and
- •<5 years of duration at the time of consent.
- •2. Active symptoms defined by a BASDAI >4.
- •3. Axial symptoms of inflammatory back pain with a less than favorable response to current intake of an NSAID at maximum tolerated dose as determined by the investigator. Subjects must have failed at least 2 NSAIDs taken separately at the maximum tolerated dose with a total combined duration of >4 weeks.
- •4. Subject must be taking a stable dose of an NSAID for at least 14 days before baseline.
- •5. Female or male 18 years or older but less than 45 years at the time of consent.
- •6. In the opinion of the investigator, subject is a reasonable candidate for treatment with etanercept.
- •7. No contraindication to MRI examination (metal implants or inability to lay flat for
- •30-60 minutes for example).
- •8. Negative serum pregnancy test taken at screening, negative urine pregnancy test taken at baseline and serum pregnancy test collected at baseline.
- •9. Agreement by male subjects who are not surgically sterile and female subjects who are not surgically sterile or post menopausal to use a highly effective method of birth control for the duration of the study.
- •10. Ability to self-inject drug or have a designee who can do so.
- •11. Ability to store injectable test article under refrigerated conditions.
- •12. Demonstrates an adequate screening for tuberculosis (TB) in accordance with local country guideline.
- •13. Subject is able to complete health outcomes assessments and test article diary.
- •Main Inclusion Criteria Period 2
- •1. Successfully completed Period 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has had previous or current treatment with any tumor necrosis factor-alpha (TNF-a) inhibitor, B/T cell inhibitor or other biologic agent.
- •2. Any orthopedic or medical condition that can cause chronic back pain (different than SpA) such as spondylodiscitis, tumor or advance discopathy.
- •3. Subjects with active uncontrolled uveitis or inflammatory bowel disease.
- •4. Radiological sacroiliitis grade is 3-4 unilaterally or grade =2 bilaterally as defined by the NY criteria
- •5. Subject has a known or suspected allergy, hypersensitivity, or contraindication to ETN, its excipients, or other compounds related to this class of medication.
- •6. Has current or recent (within 2 years) active TB infection
- •7. Serious infection (infection associated with hospitalization and/or intravenous antibiotics) within 1 month before test article administration.
- •8. Active infection at screening, including systemic fungal infections.
- •9. Presence or history of cancer (or carcinoma in situ) other than resected cutaneous basal cell or squamous cell carcinoma;
- •10. Subject has an abnormal hematology or blood chemistry at screening
- •11. Known history or presence of hepatitis B or chronic hepatitis C or HIV infection;
- •12. Subjects who are investigational site or sponsor staff , members or has direct involvement with trial
- •13. Hypertension greater than 160/100 at screening
- •14. Planned elective surgery
- •15. Subject received any live vaccines (attenuated vaccines) within 4 weeks before baseline.
- •16. Myocardial infarction within 12 months before the screening visit;
- •17. Coronary artery by pass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within 12 months before the baseline visit;
- •18. Unstable angina pectoris within 6 months before the screening visit;
- •19. Severe pulmonary disease requiring recurrent hospitalizations or supplemental oxygen;
- •20. Presence or history of confirmed blood dyscrasias;
- •21. Diagnosis of multiple sclerosis or other central or peripheral nervous system demyelinating diseases;
- •22. Presence or history of cancer (or carcinoma in situ) other than resected cutaneous basal cell or squamous cell carcinoma;
- •23. Uncontrolled diabetes mellitus;
- •24. Diagnosis of rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or polymyositis;
- •25. Open cutaneous ulcers;
- •26. Liver cirrhosis or fibrosis;
- •27. Subject has concurrent treatment with more than 1 NSAID within 14 days at baseline.
- •28. Subject has a dose of NSAID that changed within 14 days before baseline.
- •29. DMARDS other than methotrexate, sulfasalazine and hydroxychloroquine within 4 weeks of baseline.
- •30. Subject has had a dose of prednisone >10 mg/day (or equivalent) or has had a dose changed within 4 weeks before baseline.
- •31. Severe acute or chronic medical or psychiatric condition, substance abuse or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
不适用
Investigation of Early Structural Changes in Patients with Anklosing SpondyloarthritisAxial Spondyloarthritis (AxSpA)MedDRA version: 17.0Level: PTClassification code 10051265Term: SpondyloarthropathySystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-020077-16-CZPfizer Inc200
进行中（未招募）
不适用
Investigation of Early Structural Changes in Patients with Anklosing SpondyloarthritisAxial Spondyloarthritis (AxSpA)MedDRA version: 16.1Level: PTClassification code 10051265Term: SpondyloarthropathySystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-020077-16-BEPfizer Inc, 235 East 42nd Street, New York, NY 10017200
进行中（未招募）
不适用
Investigation of Early Structural Changes in Patients with Anklosing SpondyloarthritisEUCTR2010-020077-16-FIPfizer Inc, 235 East 42nd Street, New York, NY 10017200
进行中（未招募）
不适用
Investigation of Early Structural Changes in Patients with Anklosing SpondyloarthritisAxial Spondyloarthritis (AxSpA)MedDRA version: 15.0Level: PTClassification code 10051265Term: SpondyloarthropathySystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-020077-16-DEPfizer Inc, 235 East 42nd Street, New York, NY 10017200
进行中（未招募）
1 期
Investigation of Early Structural Changes in Patients with Anklosing SpondyloarthritisAxial Spondyloarthritis (AxSpA)MedDRA version: 16.1 Level: PT Classification code 10051265 Term: Spondyloarthropathy System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-020077-16-GBPfizer Inc, 235 East 42nd Street, New York, NY 10017224